Our History

KMT Hepatech, Inc. is a private company, which was founded in 2001 by Dr. Norman Kneteman, Dr. David Mercer and Dr. Lorne Tyrrell as a spin off company from the University of Alberta. The platform technology, the KMT MouseTM, is named after Drs. Kneteman, Mercer and Tyrrell.

Dr. Kneteman hypothesized that developing a method to support human liver cells in a mouse should allow support of Hepatitis C (HCV) infection, and yield a research model that would be invaluable to researchers. The attention was focused on immune deficient mice, as these mice could not reject the human liver cells when they are transplanted. A way to disadvantage a healthy mouse’s liver and enable the human liver cells to grow and replicate in the mouse model was found through the use of transgene that causes liver failure.

“Our Eureka moment was when Dr. Mercer got a call from the lab saying they had a positive test for Hep C, but that it must be a mistake, since the requisition said it was from a mouse. We knew then our research worked and we could grow human liver cells and infect these mice with Hep C,” says Dr. Kneteman.

The KMT MouseTM was widely used for drug discovery, development and pre-clinical studies. It provides an authentic viral infection model utilizing transplanted human liver cells infected with virus or parasite in a true in-vivo setting. Non-infected mice with humanized liver are utilized in safety/ toxicity and drug metabolism studies.

In 2017 KMT Hepatech became part of PhoenixBio group and will continue operations utilizing PXB-Mouse®

Board of Directors

Takashi Shimada
Norman Kneteman, MD
Yasuhrio Tamura
Yoshio Morikawa

KMT Hepatech
Dr. Norman Kneteman and Dr. Lorne Tyrrell (from Patent Portraits book by TEC Edmonton)


Our experienced team of highly skilled and knowledgeable scientific staff is able to design and execute a wide range of studies to meet your unique product development requirements.

Norman Kneteman Norm MD KMT Hepatech

Dr. Norman Kneteman

Dr. Norman Kneteman, MD, MSc, FRCSC, FACS, MS, is a Professor in the Department of Surgery at the University of Alberta and the Director of the Regional Clinical Programs in Transplantation and the Liver Transplant Program for Capital Health Authority. As the President of KMT Hepatech, Inc., he carries overall responsibility for the conducted services and research. He held the CIHR (Canadian Institutes for Health Research) / Wyeth Chair in Transplantation Research. Dr. Kneteman received his Doctor of Medicine with Distinction and Master of Science in Experimental Surgery from the University of Alberta.
Dr. Kneteman is a recipient of 40 Awards and Honors, author and co-author of 21 book chapters, 171 peer reviewed papers and 23 patents.

Dr. Lorne Tyrrell KMT Hepatech

Dr. Lorne Tyrrell
Scientific Advisor

Dr. Lorne Tyrrell, OC, AOE, MD, PhD, FRCP, FRSC is a Professor of Medicine, Biochemistry and Medical Microbiology and Immunology, and the Founding Director of the Li Ka Shing Institute of Virology, University of Alberta. Dr. Tyrrell holds the CIHR/GSK (Canadian Institutes for Health Research / GlaxoSmithKline) Chair in Virology. He received his Doctor of Medicine with Distinction from the University of Alberta and PhD in Pharmacology from Queen’s University in Ontario. His work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 170 countries worldwide for the treatment of HBV. Dr. Tyrrell is a recipient of more than 40 Awards and Honors, author and co-author of 18 book chapters, 177 peer reviewed papers, and over 50 patents.
Kaz Fortuna KMT Hepatech

Kaz Fortuna
Sr. Vice President, Operations

Kaz Fortuna, MSc., is the Sr. Vice President, Operations at KMT Hepatech. He coordinates corporate functions and manages finances, administration and HR. Mr. Fortuna has over 20 years of experience in  business and financial management with background in biotechnology, manufacturing and information technology sectors. Mr. Fortuna holds Master of Science Degree in Chemical Engineering from AGH University of Science and Technology in Cracow.

Garry Lund KMT Hepatech

Dr. Garry Lund
Vice President, Project Management

Dr. Garry Lund, PhD, is the Vice President, Project Management at KMT Hepatech, Inc. where he coordinates schedules and activities between the animal colony and analytical laboratory, manages the laboratory and works with clients to plan, coordinate and conduct studies with candidate anti-viral compounds. He received his Ph.D. in Biochemistry from the University of Alberta and continued postgraduate research in Virology at the University of Turku, Finland. Garry has over 20 years of biotechnology industrial experience in Research and Development, Quality Assurance and Clinical Affairs, supervising personnel and laboratory activities.

Svetlana Sapelnikova KMT Hepatech

Svetlana Sapelnikova
Vice President, Business Development Strategy

Dr. Svetlana Sapelnikova, PhD, MBA is involved into Marketing and Client Development at KMT Hepatech, where her responsibilities include development and refinement of company’s objectives and strategic business planning together with execution of strategic and tactical decisions in attracting new businesses and facilitating business expansion. She is the primary contact for potential clients, and she plans and coordinates company’s marketing activities. Dr. Sapelnikova holds awards in Business Planning for Technology Commercialization. She has over 10 years of the entrepreneurial experience in running businesses in both for-profit and non-for-profit settings.
She received her Ph.D. in Chemistry from Bashkir State University and MBA from the University of Alberta (Canada). Over 15 years of experience in interdisciplinary science, teaching and students supervising comes from post-graduate research in Bashkir State University (Russia), Lund University (Sweden), Institut National de la Recherche Agronomique (France), University of Alberta and National Institute for Nanotechnology (Canada). Dr. Sapelnikova is the author and co-author of over 20 peer reviewed papers.


Christine Reimer
Director, Research Planning Business Development

Christine Reimer is the most recent addition to the KMT management team and augments strategic business planning and sales, specifically in the areas of toxicity testing, and in vitro applications. She is responsible for facilitating customer relationships, and finding new business opportunities. Ms. Reimer has several years of experience in pharmaceutical sales where she developed expertise in cardiovascular, metabolic, gastrointestinal and respiratory diseases. She has a degree in pharmacology (University of Alberta) as well as basic research experience in both academia and private pharmaceutical industry.

Close Menu